Kyowa Kirin Pharmaceutical Research, Inc.
212 Carnegie Center Drive
73 articles with Kyowa Kirin Pharmaceutical Research, Inc.
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced that an abstract highlighting data and information from the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an investigational phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, will be presented during a poster discussion session at the upcoming American Society of Clinical Oncology 2022 Annual Meeting to be held June 3 – 7, 2022.
The arrangement provides the opportunity for LJI faculty and postdocs to make a more immediate impact on drug development while offering a different perspective to KKNA.
Four months after collaborating on an experimental atopic dermatitis treatment, Amgen and Kyowa Kirin are seeing the fruits of that deal with positive Phase II data.
AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase.
Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, and Synaffix B.V., a biotechnology company with a clinical-stage platform technology enabling best-in-class antibody-drug conjugates, announced the signing of a license and option agreement.
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16th International Conference on Malignant Lymphoma to be held June 18 – 22, 2021.
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Amgen and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases.
Amgen reunites with Kyowa Kirin on the development and potential commercialization of KHK4083, an atopic dermatitis drug, which impacts nearly 30 million people worldwide.
MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
Zandelisib, an investigational agent, +/- rituximab demonstrated 82% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) who had progression of disease within 24 months of first line chemoimmunotherapy (POD24); overall response rate of 93% in non-POD24
Kyowa Kirin North America Announces Key Executive Appointments in R&D and Medical Affairs As Late-Stage Assets Move Toward Key Milestones
Ernesto Aycardi, M.D. joins as Chief Development Officer and Eslie Dennis, MBChB, FCP joins as Chief Medical Officer, North America A new Global Medical Affairs Excellence function will be led by Deborah Braccia, BSN, MPA, PhD.
MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. FDA
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced completion of enrollment in the follicular lymphoma primary efficacy population of the global Phase 2 TIDAL study.
Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory
New Organizational Structure and Senior Leadership Hires Seek to Strengthen Regional Business Operations, Optimize Investments and Aid in Delivery of First-in-Class Medicines
Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, Inc., a subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151)
Harvard University and Kyowa Kirin Enter Strategic Research Alliance
Harvard University and Kyowa Kirin Co., Ltd. announce that they have entered into a strategic research alliance.
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis
Atopic dermatitis is a chronic, pruritic, inflammatory dermatosis that is believed to affect an estimated number of 26M patients in North America, EU, and Japan
New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO® (mogamulizumab-kpkc) Responders with Specific Subtypes of Cutaneous T-cell Lymphoma
Separate analyses provide insight into the characteristics of patients who respond long-term and management of drug-related rash
Kyowa Kirin North America Announces Recipients of Patient Education Grants to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)
Cutaneous Lymphoma Foundation and Lymphoma Research Foundation are Grantees from First Round of Funding Kyowa Kirin Issues a Renewed Call for Submissions, with the Grant Program Extended to 2021
Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd. announced the first patient has been dosed in the pivotal Phase 2 study of zandelisib, an oral, once-daily, investigational drug-candidate selective for phosphatidylinositol 3-kinase delta in patients with indolent B-cell non-Hodgkin's lymphoma without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström's macroglobulinemia in Japan.
Kyowa Kirin Announces Patient Education Grant Program to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, is establishing a general grant program to support the education of African-American patients about cutaneous T-cell lymphomas (CTCL) and address racial disparities in diagnosis, treatment and outcomes. Studie
Kyowa Kirin Names Finance Executive Ana Bastiani-Posner as Executive Vice President, Chief Financial Officer, North America
Kyowa Kirin USA Holdings, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, named Ana Bastiani-Posner , MBA, a proven leader with over 20 years of financial experience, as its Executive Vice President, Chief Financial Officer, effective June 29 . Ms. Bastiani-Posner